2024-12-11 - Analysis Report
## Teladoc Health Inc. (TDOC) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Teladoc Health (TDOC) significantly underperformed the S&P 500 (VOO) over the measured period.  The cumulative return for TDOC is -63.16%, while VOO's is 120.35%. This represents a substantial divergence of -183.5 percentage points.  The provided relative divergence of 0.5 indicates TDOC's performance is in the lower half of its historical performance range relative to the S&P 500.

**Company Overview:** Teladoc Health Inc. provides virtual healthcare services, including telehealth visits and related services.


**2. Recent Price Movement:**

* **Closing Price:** $10.60
* **5-Day Moving Average:** $10.82
* **20-Day Moving Average:** $10.44
* **60-Day Moving Average:** $9.51

The price is slightly above the 20-day moving average and significantly above the 60-day moving average, suggesting some potential upward momentum, but still below the 5-day average which is more of a short term indicator.


**3. Technical Indicators & Expected Return:**

* **RSI (Relative Strength Index):** 63.28 –  Indicates the stock is neither overbought nor oversold, suggesting a neutral momentum.
* **PPO (Price Oscillator):** -0.72 –  Suggests bearish momentum.
* **Recent (20-day) Relative Divergence Change:** -0.1 – Shows a recent short-term downtrend relative to the S&P 500.
* **Expected Return:** 0.0% - The provided expected return of 0% indicates that, based on the available data, no significant outperformance relative to the S&P 500 is anticipated over the long term (2+ years) with a buy and hold strategy.  This is consistent with the historical underperformance. The current price of $10.60 doesn't indicate any significant recent price jumps (no 급반등 or 급하락).


**4. Recent Earnings Analysis:**

The provided data reveals a consistent trend of negative EPS across all reported quarters. Revenue remains relatively flat around $0.64-$0.66 billion.  There is no information provided about expectations to compare the reported numbers against.

* **Latest Quarterly Results Comparison:**  The most recent quarter (2024-10-31) shows a slightly improved EPS (-$0.19) compared to the previous quarter ($-4.92) which was an outlier, indicating significant volatility in earnings.
* **Revenue Growth Trends:**  Revenue is relatively stable, showing minimal growth or decline.
* **EPS Trends:** Consistently negative, though with variability from quarter to quarter.
* **Beats or Misses:** No information on expectations is given to assess beats or misses.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, but profitability (profit margin) fluctuates slightly within a narrow range (69.89% - 71.94%).  High profit margin is notable but needs to be considered in conjunction with negative EPS.

* **Capital and Profitability:** Equity shows some variability,  and Return on Equity (ROE) is consistently negative, indicating the company is not generating returns on its equity.  This is a major concern.


**6. News and Recent Issues:**

* **Recent Earnings News:**  The provided earnings data are the most recent available information, but there's no mention of news releases within the past two days specifically related to earnings.
* **Market Outlook & Analyst Opinions:** No information is given regarding market outlook or analyst opinions on TDOC.


**7. Overall Analysis:**

Teladoc Health (TDOC) shows significant underperformance compared to the S&P 500, with consistently negative EPS and a negative ROE. Although the revenue is relatively stable and profit margins are high, these positives are overshadowed by the major concerns around negative EPS and ROE.  Technical indicators are mixed, with RSI suggesting neutrality and PPO indicating bearish momentum.  The lack of positive recent news and the consistently negative earnings picture present significant risks for investors.  The 0% expected return reflects this outlook.  Further investigation into the reasons behind the negative EPS and ROE is crucial before considering any investment.  Additional information, such as analyst opinions and news reports would further clarify the present situation and future projections.


**8. Disclaimer:** This report is based solely on the provided data. It does not constitute financial advice.  Independent research and consultation with a financial advisor are recommended before making any investment decisions.
